257 Results for "

IgG Fc

" in MedChemExpress (MCE) Product Catalog:
Products (257)

257 Results for "IgG Fc" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-P99667
CAS No.: 1391727-24-4
Synonyms: OMP-54F28; FZD8-Fc

Target:  

Wnt

Research Areas:  

Cancer

Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99930
CAS No.: 2375240-92-7
Synonyms: AKR-001; AMG-876

Target:  

FGFR

Research Areas:  

Inflammation/Immunology

Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108829
CAS No.: 332348-12-6
Purity:  ≥99.0%
Synonyms: CTLA4lg; BMS-188667

Target:  

CTLA-4

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108829A
CAS No.: 332348-12-6
Purity:  95.00%
Synonyms: CTLA4lg (powder); BMS-188667 (powder); Orencia
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99590
CAS No.: 1001080-50-7
Synonyms: ACE-011; MK-7962
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P70669
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: High affinity immunoglobulin gamma Fc receptor I; Fcgr1; FcRI; CD64; Fc receptor; IgG; high affinity I
Species:  
Source:  
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99008
CAS No.: 2417175-94-9
Synonyms: IC14
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9979
CAS No.: 1584645-37-3
Synonyms: UCB7665

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99446
CAS No.: 845264-92-8
Synonyms: TACI-Ig; TACI-Fc 5

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99395
CAS No.: 1826831-79-1
Synonyms: JNJ 56022473; CSL 362

Target:  

Interleukin Related

Research Areas:  

Cancer

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-E70365A
Research Areas:  

Inflammation/Immunology

IdeS (Immobilized, Microspin) is a resin that covalently couples IdeS protease to agarose beads and cleaves IgG at specific sites to generate F(ab')2 and Fc fragments. After IdeS (Immobilized, Microspin) digestion, F(ab')2 and Fc fragments are obtained in the solution without IdeS enzyme.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108801
CAS No.: 862111-32-8
Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

Target:  

VEGFR

Aflibercept is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70705
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FcGR3A; CD16; Prev. FcGR3; Fc Fragment Of IgG, Low Affinity IIIa, Receptor For (CD16); Prev. FcG3; Fc Of IgG Low Affinity IIIa Receptor Isoform 2; FcgammaRIIIa; Fc Of IgG Low Affinity IIIa Receptor Isoform 1; FcGRIIIA; Immunoglobulin G Fc Receptor III; CD
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108801A
CAS No.: 862111-32-8
Purity:  97.66%

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease Cancer

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-NP006
CAS No.: 308083-69-4
Synonyms: SPA
Protein A (SPA) is an immunoglobulin (Ig)-binding protein that exists on the bacterial surface and can be freely secreted into the extracellular environment. Protein A blocks opsonophagocytosis and induces B cell apoptosis in vitro by binding to the Fc region of antibodies and the Fab region of B cell receptors. Protein A can form toxic immune complexes with IgG, thereby inducing leukocyte necrosis. Protein A contributes to the virulence expression of Staphylococcus aureus. Protein A triggers allergic reactions in IgG-pretreated mouse models. Protein A can be used in studies related to immune system diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99777
CAS No.: 2131089-46-6
Synonyms: TTI-621

Target:  

CD47

Research Areas:  

Cancer

Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P72603
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Ig gamma-2A chain C region; Immunoglobulin heavy chain gamma polypeptide; Ighg
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99117
CAS No.: 2394841-59-7
Synonyms: AK104

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Inflammation/Immunology Cancer

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70771
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IGHG4; Immunoglobulin Heavy Constant Gamma 4; Immunoglobulin Heavy Constant Gamma 4 (G4m Marker); Ig Gamma-4 Chain C Region; Immunoglobulin Heavy Chain Constant Region Gamma 4
Species:  
Source:  
loading...
    loading...